Vulvar vestibular effects of ospemifene: a pilot study.

Autor: Murina F; a Lower Genital Tract Disease Unit , V. Buzzi Hospital, University of Milan , Milan , Italy., Di Francesco S; a Lower Genital Tract Disease Unit , V. Buzzi Hospital, University of Milan , Milan , Italy., Oneda S; a Lower Genital Tract Disease Unit , V. Buzzi Hospital, University of Milan , Milan , Italy.
Jazyk: angličtina
Zdroj: Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology [Gynecol Endocrinol] 2018 Jul; Vol. 34 (7), pp. 631-635. Date of Electronic Publication: 2018 Jan 15.
DOI: 10.1080/09513590.2018.1427717
Abstrakt: The study aimed to assess the effects of ospemifene on vulvar vestibule in postmenopausal women with vulvar pain and dyspareunia. Fifty-five postmenopausal women used oral ospemifene 60 mg/d for 60 d. Symptoms of dryness, burning, and dyspareunia were evaluated on a 10 cm visual analog scale. Visual examination of the vulvar vestibule was also conducted. Patients also underwent current perception threshold (CPT) testing obtained from the vulvar vestibule. Fifty-five patients (94.6%) completed the treatment. Hot flashes were the most frequent adverse effects, but this led to a discontinuation of therapy in three patients (5.4%). After therapy, there was a statistically significant decrease from the baseline in the mean scores for dryness, burning, and dyspareunia and reduction of vestibular trophic score (baseline value of 11.2-4.2 after the therapy, p ≤ 002) and cotton swab test scores (2.81 compared with 1.25, p = .001). There was a difference in CPT values for all nerve fibers and more consistent for C fibers (-38% of sensitivity). These results confirm the efficacy of ospemifene on postmenopausal vestibular symptoms and signs; moreover, the drug was effective in normalizing vestibular innervation sensitivity.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje